The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood
- PMID: 17726250
The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood
Abstract
Thromboembolic complications remain an important cause of maternal mortality. The present recommendations favour for prophylaxis unfractionated (UFH) and low molecular weight heparin (LMWH). We investigated 150 pregnant women before and after cesarean section in three randomized groups. Fifty women received no prophylaxis (group I), 50 women UFH two times 5000 IU/day (group III) and 50 women Dalteparin 5000 U/day (group II). We determined the blood count, the rheological parameters and cholesterol, triglycerides, D-dimer, fibrinogen and the anti-Xa-level. We found a classical hemodilution, with increase of erythrocyte aggregation and plasma viscosity postoperatively. The fibrinogen turnover and D-dimer concentration were elevated. The patients with Dalteparin prophylaxis showed lower thrombin activation, minor changes in the cholesterol and triglycerides level and an improvement of red cell deformability in low shear regions. Our results demonstrated an influence of Dalteparin on the rheological parameters post surgery. The DVT incidence was 1.33% generally and occurred only in the Control group and in women with unfractionated heparin. We observed no side effects such as major bleeding, osteopenia or allergy.
Similar articles
-
Changes in plasma coagulation markers with prophylactic treatment of low molecular weight heparin after cesarean section.Semin Thromb Hemost. 2005 Jun;31(3):253-60. doi: 10.1055/s-2005-872428. Semin Thromb Hemost. 2005. PMID: 16052393 Clinical Trial.
-
The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.Thromb Haemost. 2007 Jul;98(1):163-71. Thromb Haemost. 2007. PMID: 17598009 Clinical Trial.
-
Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.Obstet Gynecol. 2005 May;105(5 Pt 1):1006-11. doi: 10.1097/01.AOG.0000153026.61249.c7. Obstet Gynecol. 2005. PMID: 15863537
-
Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.Eur J Med Res. 2004 Apr 30;9(4):215-24. Eur J Med Res. 2004. PMID: 15210402 Review.
-
Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.Clin Ther. 2007 Nov;29(11):2395-405. doi: 10.1016/j.clinthera.2007.11.015. Clin Ther. 2007. PMID: 18158080 Review.
Cited by
-
The efficacy and safety of pharmacologic thromboprophylaxis following caesarean section: A systematic review and meta-analysis.PLoS One. 2018 Dec 10;13(12):e0208725. doi: 10.1371/journal.pone.0208725. eCollection 2018. PLoS One. 2018. PMID: 30532233 Free PMC article.
-
Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period.Cochrane Database Syst Rev. 2021 Mar 29;3(3):CD001689. doi: 10.1002/14651858.CD001689.pub4. Cochrane Database Syst Rev. 2021. PMID: 33779986 Free PMC article.
-
Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.Cochrane Database Syst Rev. 2010 May 12;(5):CD001689. doi: 10.1002/14651858.CD001689.pub2. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2014 Feb 11;(2):CD001689. doi: 10.1002/14651858.CD001689.pub3. PMID: 20464719 Free PMC article. Updated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical